Modification of British Committee for Standards in Haematology diagnostic criteria for essential thrombocythaemia

Harrison, Claire; Butt, Nauman M.; Campbell, Peter J.; Conneally, Eibhlin; Drummond, Mark; Green, Anthony; Murrin, Richard; Radia, Deepti; Mead, Adam J.; Reilly, John T.; Cross, Nicholas C. P.; McMullin, Mary Frances

doi:10.1111/bjh.12986

Cited by 41 publications

(50 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Case 1 reflects a frequently encountered scenario amongst patients presenting with an incidental thrombocytosis. In our centre, we utilize a diagnostic algorithm from the British Committee for Standards in Haematology (BCSH) guidelines (Harrison et al , ), shown in Fig , and investigate patients with a sustained platelet count greater than 450 × 10 9 /l. As thrombocytosis is a common finding with a wide differential diagnosis, it is important to approach the diagnostic process in a systematic manner, starting with a thorough history and examination, which is essential both for diagnosis and risk stratification.…”

Section: How We Diagnose Etmentioning

confidence: 99%

“…Algorithm for the investigation and diagnosis of thrombocytosis, adapted from the British Committee for Standards in Haematology guidelines (Harrison et al , ). *Bone marrow examination may not always be required, but is advised.…”

Section: How We Diagnose Etmentioning

confidence: 99%

“…The BCSH (Harrison et al , , , ) and World Health Organization (WHO) (Swerdlow ; Tefferi et al , , ) guidance for the diagnosis of ET are based on haematological, histological and clinical parameters but there are some important differences in the application and interpretation of different elements, as discussed below. We place particular emphasis upon excluding a potential case of chronic myeloid leukaemia.…”

Section: How We Diagnose Etmentioning

confidence: 99%

See 2 more Smart Citations

How we diagnose and treat essential thrombocythaemia

2015

Self Cite

View full text Add to dashboard Cite

SummaryThe approach to the diagnosis and management of essential thrombocythaemia (ET) is steadily changing, influenced by advances in molecular biology, data from clinical trials and retrospective analyses of patient cohorts. In the past decade options for clinical management largely remain unchanged, but who we treat, and with what target in mind, is evolving. A further area of change is recognition of symptoms that may be associated with ET, as well as other myeloproliferative neoplasms, and that potential options for their management are becoming available. Judicious and careful diagnosis is increasingly a fundamental key to successful management followed by cytoreductive therapy in a subset of patients. In this review we demonstrate our management strategies for ET using a case-based format.

show abstract

Section: How We Diagnose Etmentioning

confidence: 99%

Section: How We Diagnose Etmentioning

confidence: 99%

Section: How We Diagnose Etmentioning

confidence: 99%

See 1 more Smart Citation

How we diagnose and treat essential thrombocythaemia

2015

Self Cite

View full text Add to dashboard Cite

show abstract

“…We welcome the critical comments expressed by Harrison et al 1 as they provide an opportunity to address the impact of bone marrow (BM) morphology for the accurate diagnosis of essential thrombocythemia (ET). The readers of Leukemia are certainly aware that the first set of the original and updated BCSH diagnostic criteria (A1-A3) allows ET diagnosis without BM morphology examination (see also Table 1—Harrison et al ).…”

mentioning

confidence: 99%

“…Again, this patient group has to be classified according to the BCSH-criteria as ET as the BCSH-criteria do not recognize prePMF as an entity, separate from that of ET. 1, 4 …”

mentioning

confidence: 99%